Art. -Nr.: HY-18729

L-NAME

(Synonyms: NG-Nitroarginine methyl ester)

83 Cited Publications

Kundenbewertung

Based on 83 publication(s) in Google Scholar

L-NAME inhibits NOS with an IC₅₀ of 70 μM. L-NAME is a precursor to NOS inhibitor L-NOARG which has an IC₅₀ value of 1.4 μM. L-NAME requires hydrolysis of the methyl ester by cellular esterases to become a fully functional inhibitor. L-NAME can be used to induce hypertension and preeclampsia models.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 50903-99-6
Formel: C₇H₁₅N₅O₄
Molecular Weight:233.23

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (276 KB)

L-NAME Chemical Structure

CAS. Nr.: 50903-99-6

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- Cellular Effect
- In Vitro
- Induced Disease Models
- Clinical Trial
Chemical Information
Publications (83)
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

Alle NO Synthase Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
BV-2	IC₅₀	13.35 μM Compound: L-NAME	Inhibition of iNOS-mediated nitric oxide production in LPS-stimulated mouse BV2 cells measured after 24 hrs of post-stimulation by Griess reaction method Inhibition of iNOS-mediated nitric oxide production in LPS-stimulated mouse BV2 cells measured after 24 hrs of post-stimulation by Griess reaction method	[PMID: 22115618]
BV-2	IC₅₀	18.9 μM Compound: L-NAME	Inhibition of Nitric oxide synthase activity in mouse BV2 cells assessed as LPS-induced NO production after 24 hrs by Griess reaction Inhibition of Nitric oxide synthase activity in mouse BV2 cells assessed as LPS-induced NO production after 24 hrs by Griess reaction	[PMID: 21377368]
BV-2	IC₅₀	20.1 μM Compound: L-NAME	Inhibition of nitric oxide synthase in mouse BV2 cells assessed as inhibition of LPS-induced NO production Inhibition of nitric oxide synthase in mouse BV2 cells assessed as inhibition of LPS-induced NO production	[PMID: 18161942]
BV-2	IC₅₀	24.7 μM Compound: NAME	Inhibition of LPS-induced NO production in mouse BV2 cells preincubated for 1 hr followed by LPS addition measured after 24 hrs by Griess assay Inhibition of LPS-induced NO production in mouse BV2 cells preincubated for 1 hr followed by LPS addition measured after 24 hrs by Griess assay	[PMID: 27588326]
BV-2	IC₅₀	25.8 μM Compound: L-NAME	Inhibition of iNOS-mediated NO production in LPS-induced mouse BV2 cells Inhibition of iNOS-mediated NO production in LPS-induced mouse BV2 cells	[PMID: 18926710]
BV-2	IC₅₀	25.8 μM Compound: L-NAME	Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced iNOS-dependent nitrite production after 24 hrs by Griess method Antiinflammatory activity in mouse BV2 cells assessed as inhibition of LPS-induced iNOS-dependent nitrite production after 24 hrs by Griess method	[PMID: 21028898]
BV-2	IC₅₀	36 μM Compound: L-NAME	Inhibition of NOS-dependent nitric oxide production in mouse BV2 cells Inhibition of NOS-dependent nitric oxide production in mouse BV2 cells	[PMID: 17046255]
DLD-1	IC₅₀	>300 μM Compound: 2'	Inhibitory activity against synthesis of inducible nitric oxide synthase by DLD-1 cells Inhibitory activity against synthesis of inducible nitric oxide synthase by DLD-1 cells	[PMID: 12620067]
DLD-1	IC₅₀	14 μM Compound: 2b	Ability to inhibit conversion of [3H]L-Arg to [3H]L-citrulline catalyzed by inducible NOS (i NOS) from human DLD-1 cells Ability to inhibit conversion of [3H]L-Arg to [3H]L-citrulline catalyzed by inducible NOS (i NOS) from human DLD-1 cells	[PMID: 11327580]
DLD-1	IC₅₀	300 mM Compound: 2b	Inhibitory concentration against nitric oxide synthesis in intact DLD-1 cells Inhibitory concentration against nitric oxide synthesis in intact DLD-1 cells	[PMID: 11327580]
HUVEC	IC₅₀	2.7 μM Compound: 2b	Ability to inhibit conversion of [3H]L-Arg to [3H]L-citrulline catalyzed by endothelial NOS (e NOS) from HUVEC cells Ability to inhibit conversion of [3H]L-Arg to [3H]L-citrulline catalyzed by endothelial NOS (e NOS) from HUVEC cells	[PMID: 11327580]
J774.A1	IC₅₀	73.18 μM Compound: L-NAME	Antiinflammatory activity in mouse J774A1 cells assessed as inhibition of LPS-induced NO production incubated for 1 hr prior to LPS challenge measured after 24 hrs by Griess method Antiinflammatory activity in mouse J774A1 cells assessed as inhibition of LPS-induced NO production incubated for 1 hr prior to LPS challenge measured after 24 hrs by Griess method	[PMID: 24909081]
J774.A1	IC₅₀	73.18 μM Compound: L-NAME	Inhibition of LPS-induced NO production in mouse J774A1 cells compound preincubated for 1 hr before LPS treatment by Griess reaction Inhibition of LPS-induced NO production in mouse J774A1 cells compound preincubated for 1 hr before LPS treatment by Griess reaction	[PMID: 25113933]
J774.A1	IC₅₀	73.18 μM Compound: L-NAME	Inhibition of LPS-induced nitric oxide production in mouse J774A.1 cells pre-incubated for 1 hr followed by LPS stimulation for 24 hrs by Griess reagent based assay Inhibition of LPS-induced nitric oxide production in mouse J774A.1 cells pre-incubated for 1 hr followed by LPS stimulation for 24 hrs by Griess reagent based assay	[PMID: 25824662]
N9	IC₅₀	0.63 mM Compound: L-NAME	Antiinflammatory activity against mouse N9 cells assessed as inhibition of LPS/IFN-gamma-induced nitrite accumulation treated 1 hr before LPS challenge assessed after 24 hrs Antiinflammatory activity against mouse N9 cells assessed as inhibition of LPS/IFN-gamma-induced nitrite accumulation treated 1 hr before LPS challenge assessed after 24 hrs	[PMID: 11087610]
RAW264.7	IC₅₀	116.2 μM Compound: L-NAME	Antiinflammatory activity against mouse RAW264.7 assessed as inhibition of IFN-gamma-induced NO production after 24 hrs Antiinflammatory activity against mouse RAW264.7 assessed as inhibition of IFN-gamma-induced NO production after 24 hrs	[PMID: 11000020]
RAW264.7	IC₅₀	170.04 μM Compound: L-NAME	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production after 24 hrs by Griess method	[PMID: 23566521]
RAW264.7	IC₅₀	198.3 μM Compound: L-NAME	Antiinflammatory activity against mouse RAW264.7 assessed as inhibition of LPS-induced NO production after 24 hrs Antiinflammatory activity against mouse RAW264.7 assessed as inhibition of LPS-induced NO production after 24 hrs	[PMID: 11000020]
RAW264.7	IC₅₀	23.21 μM Compound: 9a, L-NAME	Anti-inflammatory activity in Mus musculus (mouse) RAW264.7 cells assessed as inhibition of IFN-gamma/LPS-induced NO production after 17 to 20 hr by Griess assay Anti-inflammatory activity in Mus musculus (mouse) RAW264.7 cells assessed as inhibition of IFN-gamma/LPS-induced NO production after 17 to 20 hr by Griess assay	10.1007/s00044-011-9706-1
RAW264.7	IC₅₀	26.21 μM Compound: L-NAME	Anti-inflammatory activity in Mus musculus (mouse) RAW264.7 cells assessed as inhibition of IFN-gamma/LPS-induced nitric oxide production after 17 to 20 hr by Griess assay Anti-inflammatory activity in Mus musculus (mouse) RAW264.7 cells assessed as inhibition of IFN-gamma/LPS-induced nitric oxide production after 17 to 20 hr by Griess assay	10.1007/s00044-010-9521-0
RAW264.7	IC₅₀	27.13 μM Compound: L-NAME	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of IFN-gamma/LPS-stimulated nitric oxide production after 17 to 20 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of IFN-gamma/LPS-stimulated nitric oxide production after 17 to 20 hrs by Griess assay	[PMID: 19359068]
RAW264.7	IC₅₀	30.6 μM Compound: L-Name	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 2 hrs followed by LPS stimulation measured after 18 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitric oxide production preincubated for 2 hrs followed by LPS stimulation measured after 18 hrs by Griess assay	[PMID: 28099011]
RAW264.7	IC₅₀	48.5 μM Compound: L-NAME	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells preincubated with compound for 1 hr before exposure to LPS measured after 24 hrs by Griess reaction method Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells preincubated with compound for 1 hr before exposure to LPS measured after 24 hrs by Griess reaction method	[PMID: 21435874]
RAW264.7	IC₅₀	53.6 μM Compound: L-NAME	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 1 hr prior to LPS-challenge measured after 24 hrs by Greiss assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 1 hr prior to LPS-challenge measured after 24 hrs by Greiss assay	[PMID: 25412141]
RAW264.7	IC₅₀	58.4 μM Compound: L-NAME	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitirc oxide production pretreated followed by LPS challenge and measured after 24 hrs by Griess assay Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced nitirc oxide production pretreated followed by LPS challenge and measured after 24 hrs by Griess assay	[PMID: 32319765]
RAW264.7	IC₅₀	69.21 μM Compound: L-NAME	Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 1 hr prior to LPS challenge measured after 24 hrs by Griess method Antiinflammatory activity in mouse RAW264.7 cells assessed as inhibition of LPS-induced NO production incubated for 1 hr prior to LPS challenge measured after 24 hrs by Griess method	[PMID: 24909081]
RAW264.7	IC₅₀	69.21 μM Compound: L-NAME	Inhibition of LPS-induced NO production in mouse RAW264.7 cells compound preincubated for 1 hr before LPS treatment by Griess reaction Inhibition of LPS-induced NO production in mouse RAW264.7 cells compound preincubated for 1 hr before LPS treatment by Griess reaction	[PMID: 25113933]
RAW264.7	IC₅₀	69.21 μM Compound: L-NAME	Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells pre-incubated for 1 hr followed by LPS stimulation for 24 hrs by Griess reagent based assay Inhibition of LPS-induced nitric oxide production in mouse RAW264.7 cells pre-incubated for 1 hr followed by LPS stimulation for 24 hrs by Griess reagent based assay	[PMID: 25824662]

In Vitro

L-arginine analogues are widely used inhibitors of nitric oxide synthase (NOS) activity, with N^w-nitro-L-arginine methyl ester (L-NAME) being at the head^[2]. Freshly dissolved L-NAME is a 50 fold less potent inhibitor of purified brain NOS (mean IC₅₀= 70 μM) than L-NOARG (IC₅₀= 1.4 μM), but the apparent inhibitory potency of L-NAME approached that of L-NOARG upon prolonged incubation at neutral or alkaline pH. HPLC analyses reveal that NOS inhibition by L-NAME closely correlated with hydrolysis of the drug to L-NOARG^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Induced Disease Models

Note:
Please do not refer to only one article to determine the experimental conditions. It is recommended to determine the optimal experimental conditions (animal strain, age, dosage, frequency and cycle, detection time and indicators, etc.) through preliminary experiments before the formal experiment.

L-NAME hydrochloride can be used to induce hypertension models^[6].

Induction of hypertension Model^[6]

Background

L-NAME hydrochloride decreases nitric oxide (NO) release with an inhibition competence in endothelial nitric oxide synthase (eNOS) in animals.

Specific Modeling Methods

Mice: Swiss Webster • male • 6-week-old
Administration: 400 mg/kg • ip • once daily for 7 days

Modeling Indicators

Body quality changes: Induced hypertension with body weight loss and high blood pressure.

2. Induction of preeclampsia^[8]

Background

L-NAME induces preeclampsia by reducing the production of nitric oxide through inhibiting nitric oxide synthase, triggering a series of changes such as vasoconstriction, placental dysfunction, inflammatory response, and anti-angiogenesis.

Specific Modeling Methods

Mice: CBA x C57BL/6 pregnant female mice • 6-16 weeks old
Administration: subcutaneous injection • 50 mg/kg/day • E7.5 to E17.5

Modeling Indicators

Elevated blood pressure, impaired fetal and placental growth, and increased circulating endothelin-1 (vasoconstrictor), soluble fms-like tyrosine kinase-1 (anti-angiogenic factor), and C-reactive protein (inflammatory marker).

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Clinical Trial

NCT Number	Sponsor	Condition	Start Date	Phase A549
NCT01329991	Plexxikon\|		2011-05	PHASE1

Chemical Information

CAS. Nr. 50903-99-6
Molecular Weight 233.23
Formel C₇H₁₅N₅O₄
SMILES

N[C@@H](CCCNC(N[N+]([O-])=O)=N)C(OC)=O
Synonyms

NG-Nitroarginine methyl ester
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Publications (83)

All WBIF

Sort by:

Journal Impact Factor

Signal Transduct Target Ther

Arginase 1 drives mitochondrial cristae remodeling and PANoptosis in ischemia/hypoxia-induced vascular dysfunction. [Abstract]

2025 May 28;10(1):167. PMID: 40425583
Cancer Res

Oncogenic KRAS induces arginine auxotrophy and confers a therapeutic vulnerability to SLC7A1 inhibition in non-small cell lung cancer. [Abstract]

2024 Jun 14;84(12):1963-1977. PMID: 38502865
J Extracell Vesicles

Extracellular vesicles derived from Akkermansia muciniphila promote placentation and mitigate preeclampsia in a mouse model. [Abstract]

2023 May;12(5):e12328. PMID: 37165987
Adv Sci (Weinh)

Cuproptosis and Disulfidptosis Converge to Empower PD-L1 Checkpoint Therapy via Cadict-Induced PD-L1 Translation. [Abstract]

2026 May;13(25):e15367. PMID: 41722054
Adv Sci (Weinh)

Thrombospondin-1 Regulates Trophoblast Necroptosis via NEDD4-Mediated Ubiquitination of TAK1 in Preeclampsia. [Abstract]

2024 Jun;11(21):e2309002. PMID: 38569496
J Adv Res

2026 May 21:S2090-1232(26)00436-4. PMID: 42173361
J Nanobiotechnology

Sparking angiogenesis by carbon monoxide-rich gold nanoparticles obtained by pulsed laser driven CO2 reduction reaction. [Abstract]

2025 Aug 26;23(1):590. PMID: 40859339
Hum Reprod Open

Impaired PIEZO1 function drives uterine hypercontractility in adenomyosis-associated dysmenorrhea. [Abstract]

2026 Feb 17;2026(2):hoag013. PMID: 41836349
Cardiovasc Diabetol

MAP4K4 exacerbates cardiac microvascular injury in diabetes by facilitating S-nitrosylation modification of Drp1. [Abstract]

2024 May 9;23(1):164. PMID: 38724987
Cell Commun Signal

Histone deacetylase 3 inhibition alleviates type 2 diabetes mellitus-induced endothelial dysfunction via Nrf2. [Abstract]

2021 Mar 18;19(1):35. PMID: 33736642
Phytomedicine

Triterpenoid saponins from Ilex pubescens promote blood circulation in blood stasis syndrome by regulating sphingolipid metabolism and the PI3K/AKT/eNOS signaling pathway. [Abstract]

2022 Sep:104:154242. PMID: 35728385
Free Radic Biol Med

Intermedin protects peritubular capillaries by inhibiting eNOS uncoupling through AMPK/GTPCH-I/BH4 pathway and alleviate CKD following AKI. [Abstract]

2025 Apr 12:S0891-5849(25)00225-4. PMID: 40228707
Free Radic Biol Med

TRPA1 protects against contrast-induced renal tubular injury by preserving mitochondrial dynamics via the AMPK/DRP1 pathway. [Abstract]

2024 Sep 13:S0891-5849(24)00659-2. PMID: 39278575
Biomed Pharmacother

Nicorandil reversed homocysteine-induced coronary microvascular dysfunction via regulating PI3K/Akt/eNOS pathway. [Abstract]

2020 Jul:127:110121. PMID: 32407984
Biomed Pharmacother

A low-salt diet with candesartan administration is associated with acute kidney injury in nephritis by increasing nitric oxide. [Abstract]

2023 May:161:114484. PMID: 36921530

L-NAME purchased from MedChemExpress. Usage Cited in: Biomed Pharmacother. 2023 May:161:114484. [Abstract]

L-NAME (10 mg/kg; i.p.; single daily for 7 days; pretreat) alleviates Candesartan-induced glomerular shrinkage and renal tubular necrosis and detachment, in low-salt rats.
Biomed Pharmacother

Antihypertensive effects of allicin on spontaneously hypertensive rats via vasorelaxation and hydrogen sulfide mechanisms. [Abstract]

2020 Aug;128:110240. PMID: 32480217
Biomed Pharmacother

Ginsenoside Re inhibits PDGF-BB-induced VSMC proliferation via the eNOS/NO/cGMP pathway. [Abstract]

2019 Jul:115:108934. PMID: 31082773
Arterioscler Thromb Vasc Biol

Endothelial Scaffolding Protein ENH (Enigma Homolog Protein) Promotes PHLPP2 (Pleckstrin Homology Domain and Leucine-Rich Repeat Protein Phosphatase 2)-Mediated Dephosphorylation of AKT1 and eNOS (Endothelial NO Synthase) Promoting Vascular Remodeling. [Abstract]

2020 Jul;40(7):1705-1721. PMID: 32268790
Aging Cell

Vascular Endothelial NAMPT-Mediated NAD+ Biosynthesis Regulates Angiogenesis and Cardiometabolic Functions in Male Mice. [Abstract]

2025 Sep 29:e70222. PMID: 41021357
Aging Cell

Aging-Associated Liver Sinusoidal Endothelial Cells Dysfunction Aggravates the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease. [Abstract]

2025 Feb 6:e14502. PMID: 39912563
JCI Insight

Roxadustat prevents Ang II hypertension by targeting angiotensin receptors and eNOS. [Abstract]

2021 Sep 22;6(18):e133690. PMID: 34403364
Int J Mol Med

Naringenin modulates the NO‑cGMP‑PKG signaling pathway by binding to AKT to enhance osteogenic differentiation in hPDLSCs. [Abstract]

2024 Aug;54(2):67. PMID: 38940332
Biochem Pharmacol

2026 Sep;251(Pt 1):118081. PMID: 42162768
Chem Biol Interact

Platycodin D reverses tumor necrosis factor-α-induced endothelial dysfunction by increasing nitric oxide through G protein-coupled estrogen receptor-mediated eNOS activity. [Abstract]

2025 May 28:111577. PMID: 40447174
J Ethnopharmacol

Ginkgo biloba L. extract prevents steroid-induced necrosis of the femoral head by rescuing apoptosis and dysfunction in vascular endothelial cells via the PI3K/AKT/eNOS pathway. [Abstract]

2022 Oct 5:296:115476. PMID: 35724747
Cancer Metab

Hypoxia-induced NOS1 as a therapeutic target in hypercholesterolemia-related colorectal cancer. [Abstract]

2024 May 17;12(1):14. PMID: 38755702
Commun Biol

GDF11 alleviates glucocorticoid-induced osteonecrosis of the femoral head by regulating angiogenesis via the PI3K-AKT-eNOS pathway. [Abstract]

2025 Nov 25;8(1):1682. PMID: 41291036
Nutrients

Puerariae lobatae Radix Alleviates Pre-Eclampsia by Remodeling Gut Microbiota and Protecting the Gut and Placental Barriers. [Abstract]

2022 Nov 25;14(23):5025. PMID: 36501055
Biol Direct

miR-155 mediated regulation of PKG1 and its implications on cell invasion, migration, and apoptosis in preeclampsia through NF-κB pathway. [Abstract]

2024 Nov 26;19(1):121. PMID: 39587640
Int J Mol Sci

The Enzyme 15-Hydroxyprostaglandin Dehydrogenase Inhibits a Shift to the Mesenchymal Pattern of Trophoblasts and Decidual Stromal Cells Accompanied by Prostaglandin Transporter in Preeclampsia. [Abstract]

2023 Mar 7;24(6):5111. PMID: 36982197
Int Immunopharmacol

Targeting periodontal inflammatory microenvironment to ameliorate periodontitis: A nitrogen ions implantation technique. [Abstract]

2025 Dec 24:170:116055. PMID: 41448003
Am J Physiol Cell Physiol

Endothelial Protective Effects of Ferulic Acid in Pre-eclampsia Treatment. [Abstract]

2025 Oct 30. PMID: 41165539
Int Immunopharmacol

CTRP13 attenuates atherosclerosis by inhibiting endothelial cell ferroptosis via activating GCH1. [Abstract]

2024 Nov 13;143(Pt 3):113617. PMID: 39541845
Int Immunopharmacol

Epigenetic modification of TWIST1 in macrophages promotes hypertension-induced atherosclerotic plaque instability. [Abstract]

2024 Jan 25:127:111313. PMID: 38134595
Clin Epigenetics

WTAP regulates NCOA4-mediated ferroptosis via a YTHDF2-dependent mechanism in preeclampsia. [Abstract]

2025 Nov 19;17(1):195. PMID: 41257944
J Mol Med (Berl)

Astragaloside IV inhibits the progression of hypertensive heart disease via the RXRA/PPARG/SIRT3 axis. [Abstract]

2025 Dec 16;104(1):6. PMID: 41402523
FASEB J

Nitric Oxide Scavenging Alleviates Scar Pruritus by Inhibiting S-Nitrosylation of Transient Receptor Potential Channels and Limiting Calcium Influx. [Abstract]

2025 Jul 31;39(14):e70817. PMID: 40637249
FASEB J

The Effect of FPR2 on the Regulation of Trophoblast Autophagy via the PI3K/AKT/mTOR Signaling Pathway in Preeclampsia. [Abstract]

2025 Jun 15;39(11):e70697. PMID: 40474580
Microorganisms

Pasteurized Akkermansia muciniphila Ameliorates Preeclampsia in Mice by Enhancing Gut Barrier Integrity, Improving Endothelial Function, and Modulating Gut Metabolic Dysregulation. [Abstract]

2024 Dec 2;12(12):2483. PMID: 39770686
FASEB J

Desaminotyrosine is a redox-active microbial metabolite that bolsters macrophage antimicrobial functions while attenuating IL-6 production. [Abstract]

2024 Jul 31;38(14):e23844. PMID: 39046365
J Cell Mol Med

NEDD4L is a promoter for angiogenesis and cell proliferation in human umbilical vein endothelial cells. [Abstract]

2024 Apr;28(8):1-11. PMID: 38526036
Bioengineered

Knockdown of forkhead box protein P1 alleviates hypoxia reoxygenation injury in H9c2 cells through regulating Pik3ip1/Akt/eNOS and ROS/mPTP pathway. [Abstract]

2022 Jan;13(1):1320-1334. PMID: 35000528
Mediators Inflamm

Activating CD137 Signaling Promotes Sprouting Angiogenesis via Increased VEGFA Secretion and the VEGFR2/Akt/eNOS Pathway. [Abstract]

2020 Oct 24;2020:1649453. PMID: 33162828
Mediators Inflamm

Andrographolide Protects against HG-Induced Inflammation, Apoptosis, Migration, and Impairment of Angiogenesis via PI3K/AKT-eNOS Signalling in HUVECs. [Abstract]

2019 Oct 7;2019:6168340. PMID: 31686985
Hum Gene Ther

HIV Tat- conjugated Histone H3 peptides induce tumor cell death via cellular stress responses. [Abstract]

2023 Jan;34(1-2):42-55. PMID: 36373826
Sci Rep

Gnetum montanum extract attenuates lipopolysaccharide induced acute lung inflammation through Nrf2 and heme oxygenase 1 mediated redox modulation in macrophages. [Abstract]

2026 Apr 24;16(1):18995. PMID: 42031984
Sci Rep

TET1 modulates trophoblast function by regulation of ODC1 in preeclampsia. [Abstract]

2025 Oct 31;15(1):38208. PMID: 41174031
Front Med

Erythropoietin Attenuates Experimental Contrast-Induced Nephrology: A Role for the Janus Kinase 2/Signal Transducer and Activator of Transcription 3 Signaling Pathway. [Abstract]

2021 Apr 13:8:634882. PMID: 33928100
Toxicol Appl Pharmacol

M1 macrophage mediated increased reactive oxygen species (ROS) influence wound healing via the MAPK signaling in vitro and in vivo. [Abstract]

2019 Mar 1:366:83-95. PMID: 30690042
Bosn J Basic Med Sci

Nitric oxide synthesis-promoting effects of valsartan in human umbilical vein endothelial cells via the Akt/adenosine monophosphate-activated protein kinase/endothelial nitric oxide synthase pathway. [Abstract]

2017 May 20;17(2):132-137. PMID: 28178430

L-NAME purchased from MedChemExpress. Usage Cited in: Bosn J Basic Med Sci. 2017 May 20;17(2):132-137. [Abstract]

Effects of Akt/adenosine monophosphate-activated protein kinaseon CGP 48933 (VAL)-mediated endothelial nitric oxide (NO) synthase (eNOS) phosphorylation and NO production in human umbilical vein endothelial cells (HUVECs). (A) The variation of VAL (10 μM)-induced eNOS activation after HUVECs are incubated with LY294002 [LY] (10 μM), Compound C (1 μM), L-NAME (500 μM) for 3 hours. (B)The variation of VAL (10 μM)-induced nitric oxide (NO) productionafter HUVECs are incubated with LY294002 (10 μM),
Int J Med Sci

Deficiency of Caveolin-1 Aggravates Cardiac Infarction Injury by Disturbing the Endothelial Homeostasis. [Abstract]

2025 Jan 21;22(4):920-932. PMID: 39991756
Ren Fail

2026 Dec;48(1):2646089. PMID: 41912450
Mol Cell Probes

Elevated PGT promotes proliferation and inhibits cell apoptosis in preeclampsia by Erk signaling pathway. [Abstract]

2023 Feb:67:101896. PMID: 36731680
Peptides

Apelin/APJ increased renal blood flow through endothelial BKCa channel induced p-eNOS and ET-1 in diabetic conditions. [Abstract]

2024 Dec 5:183:171333. PMID: 39644975
Cell Tissue Res

Esomeprazole inhibits hypoxia/endothelial dysfunction-induced autophagy in preeclampsia. [Abstract]

2022 Apr;388(1):181-194. PMID: 35091806
Front Cardiovasc Med

Downregulation of Cullin 3 Ligase Signaling Pathways Contributes to Hypertension in Preeclampsia. [Abstract]

2021 Apr 13:8:654254. PMID: 33928137
Microvasc Res

Gastrodin protects endothelial cells against high glucose-induced injury through up-regulation of PPARβ and alleviation of nitrative stress. [Abstract]

2023 Jul:148:104531. PMID: 36963481
Vet Microbiol

PDZK1 upregulates nitric oxide production through the PI3K/ERK2 pathway to inhibit porcine circovirus type 2 replication. [Abstract]

2022 Sep:272:109514. PMID: 35917623
Int J Immunopathol Pharmacol

Formononetin regulates endothelial nitric oxide synthase to protect vascular endothelium in deep vein thrombosis rats. [Abstract]

2022 Jan-Dec:36:3946320221111117. PMID: 35731855
Clin Exp Pharmacol Physiol

2026 Jun;53(6):e70140. PMID: 42264451
Clin Exp Pharmacol Physiol

Indole-3-Propionic Acid Improves Vascular Function in High-Fat Diet-Induced Obese Mice via eNOS. [Abstract]

2025 Nov;52(11):e70081. PMID: 41057979
J Cardiovasc Transl Res

TMAO Impairs Mouse Aortic Vasodilation by Inhibiting TRPV4 Channels in Endothelial Cells. [Abstract]

2024 Dec;17(6):1415-1426. PMID: 38980653
Placenta

Cyclosporin A alleviates trophoblast apoptosis and senescence by promoting autophagy in preeclampsia. [Abstract]

2022 Jan:117:95-108. PMID: 34785431
Placenta

ELABELA alleviates syncytiotrophoblast hypoxia/reoxygenation injury and preeclampsia-like symptoms in mice by reducing apoptosis. [Abstract]

2021 Mar:106:30-39. PMID: 33610935
BMC Nephrol

Sodium selenite attenuates inflammatory response and oxidative stress injury by regulating the Nrf2/ARE pathway in contrast-induced acute kidney injury in rats. [Abstract]

2024 Jul 15;25(1):226. PMID: 39009991
PeerJ

PFI-3 induces vasorelaxation with potency to reduce extracellular calcium influx in rat mesenteric artery. [Abstract]

2023 May 25:11:e15407. PMID: 37250720
Insect Mol Biol

A parasitoid regulates 20E synthesis and antibacterial activity of the host for development by inducing host nitric oxide production. [Abstract]

2024 Jun;33(3):206-217. PMID: 38180144
Biomed Res Int

Gentiopicroside Produces Endothelium-Independent Vasodilation by Deactivating the PI3K/Akt/Rho-Kinase Pathway in Isolated Rat Thoracic Aorta. [Abstract]

2021 May 14:2021:5565748. PMID: 34095301
Exp Ther Med

Effects of ginsenoside Rb1 on oxidative stress injury in rat spinal cords by regulating the eNOS/Nrf2/HO-1 signaling pathway. [Abstract]

2018 Aug;16(2):1079-1086. PMID: 30116359

L-NAME purchased from MedChemExpress. Usage Cited in: Exp Ther Med. 2018 Aug;16(2):1079-1086. [Abstract]

Effect of L-name on the expression of eNOS, HSP90, Nrf2, Nqo1 and HO-1 in a rat model of spinal cord injury (SCI).
Sex Med

Hinokiflavone alleviates high-fat diet-induced erectile dysfunction via the EGFR/PI3K/Akt/eNOS signaling pathway. [Abstract]

2025 Aug 6;13(4):qfaf059. PMID: 40808867
Physiol Rep

Glutamine enhances endothelial cell survival and vasodilation by increasing glutathione to reduce oxidative stress. [Abstract]

2026 Jan;14(2):e70737. PMID: 41566950
Int Heart J

Exploring the Role and Mechanism of DSF in HFpEF Based on IL-1β/IL-1βR/TAK1/RIPK1 Axis-Mediated PANoptosis. [Abstract]

2026;67(1):65-76. PMID: 41621910
Brain Dev

L-NAME improves the morphology and necrosis of skeletal muscle by activating PINK1-PARKIN mediated mitophagy in mdx mice. [Abstract]

2025 Jul 1;47(4):104388. PMID: 40602311
Exp Anim

Integrative network pharmacology and experimental study of Qingda granule in hypertension-induced endothelial dysfunction. [Abstract]

2025 Oct 30. PMID: 41161798
Res Sq

2025 Nov 12.
bioRxiv

2025 May 06.
University of Jena

2023 Dec.
bioRxiv

2023 Dec 4.
bioRxiv

2023 Nov 1.
Research Square Preprint

2023 May 30.
Research Square Preprint

2022 May.
Research Square Preprint

2021 Feb.
Evid Based Complement Alternat Med

Acupuncture at Gastric Back-Shu and Front-Mu Acupoints Enhances Gastric Motility via the Inhibition of the Glutamatergic System in the Hippocampus. [Abstract]

2020 Mar 10;2020:3524641. PMID: 32215036

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (276 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Pfeiffer S, et al. Inhibition of nitric oxide synthesis by NG-nitro-L-arginine methyl ester (L-NAME): requirement forbioactivation to the free acid, NG-nitro-L-arginine. Br J Pharmacol. 1996 Jul;118(6):1433-40. [Content Brief]

[2]. Kopincová J, et al. L-NAME in the cardiovascular system - nitric oxide synthase activator? Pharmacol Rep. 2012;64(3):511-20. [Content Brief]

[3]. Lo HC, et al. The Nitric Oxide Synthase Inhibitor NG-Nitro-L-Arginine Methyl Ester Diminishes the Immunomodulatory Effects of Parental Arginine in Rats with Subacute Peritonitis. PLoSOne. 2016 Mar 23;11(3):e0151973. [Content Brief]

[4]. Luo H, et al. Effect of nitric oxide synthase inhibitor L-NAME on fear extinction in rats: a task-dependent effect. Neurosci Lett. 2014 Jun 20;572:13-8. [Content Brief]

[5]. Ocsan RJ, et al. Chronic NG-nitro-l-arginine methyl ester (L-NAME) administration in C57BL/6J mice induces a sustained decrease in c-kit positive cells during development of cardiac hypertrophy. J Physiol Pharmacol. 2013 Dec;64(6):727-36. [Content Brief]

[6]. V A Peotta, et al. Cardiovascular neural reflexes in L-NAME-induced hypertension in mice. Hypertension. 2001, 38, 3. [Content Brief]

[7]. Xiaofei Li, et al. Fucoidan from Undaria pinnatifida prevents vascular dysfunction through PI3K/Akt/eNOS-dependent mechanisms in the l-NAME-induced hypertensive rat model. Food Funct. 2016, 7, 5. [Content Brief]

[8]. de Alwis N, et al. The L-NAME mouse model of preeclampsia and impact to long-term maternal cardiovascular health. Life Sci Alliance. 2022 Aug 5;5(12):e202201517. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Keywords

L-NAME

83 Cited Publications

100 mg Angebot einholen

Subscribe to the

MedChemExpress

Newsletter

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

L-NAME

Publications Citing Use of MedChemExpress (MCE) L-NAME

Alle NO Synthase Isoform-spezifische Produkte anzeigen

Biologische Aktivität

Chemical Information

Publications (83)

Reinheit & Dokumentation

Verweise

Calculators

Help & FAQs

L-NAME Related Classifications

HY-18729 Related Classifications